Education
About Us
Working with TipRanks
Follow Us
Standard BioTools (LAB)
NASDAQ:LAB
LAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.92 - $2.32
Previous CloseN/A
Volume335.74K
Average Volume (3M)1.21M
Market Cap
$496.59M
Enterprise Value$248.13M
Total Cash (Recent Filing)$237.09M
Total Debt (Recent Filing)$28.62M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 11, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding381,995,120
10 Day Avg. Volume1,210,937
30 Day Avg. Volume1,211,200
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue1.61
Enterprise Value/Gross Profit3.71
Enterprise Value/Ebitda-2.72
Forecast
1Y Price Target
$1.55Price Target Upside19.23% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLAB reported 1Q revenue slightly better than consensus estimates, which is a good result in light of ongoing macro pressures and share weakness.
Operational ImprovementSolid operational expense controls showcase operational improvement despite gross margin miss due to mix and volume.
Bears Say
Growth OutlookThe sale of SomaLogic has led to a lower growth outlook for Standard Biotools Inc.
Market ExposureThere is a higher exposure to ongoing market headwinds, including US Academic funding and soft capital expenditure trends.
Near-term CatalystsFewer near-term catalysts are available to drive shares higher following the sale of SomaLogic.
Standard BioTools News
LAB FAQ
What was Standard BioTools’s price range in the past 12 months?
Standard BioTools lowest stock price was $0.92 and its highest was $2.32 in the past 12 months.
What is Standard BioTools’s market cap?
Standard BioTools’s market cap is $496.59M.
When is Standard BioTools’s upcoming earnings report date?
Standard BioTools’s upcoming earnings report date is Nov 11, 2025 which is in 65 days.
How were Standard BioTools’s earnings last quarter?
Standard BioTools released its earnings results on Aug 11, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.017.
Is Standard BioTools overvalued?
According to Wall Street analysts Standard BioTools’s price is currently Undervalued.
Does Standard BioTools pay dividends?
Standard BioTools does not currently pay dividends.
What is Standard BioTools’s EPS estimate?
Standard BioTools’s EPS estimate is -0.04.
How many shares outstanding does Standard BioTools have?
Standard BioTools has 381,995,120 shares outstanding.
What happened to Standard BioTools’s price movement after its last earnings report?
Standard BioTools reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went up 2.344%.
Which hedge fund is a major shareholder of Standard BioTools?
Currently, no hedge funds are holding shares in LAB
Standard BioTools Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.55 (19.23% Upside)
$1.55 (19.23% Upside)
Blogger Sentiment
Bullish
LAB Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 258.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.67%
12-Months-Change
Fundamentals
Return on Equity
-22.40%
Trailing 12-Months
Asset Growth
-21.41%
Trailing 12-Months
Company Description
Standard BioTools
Standard BioTools (LAB) is a biotechnology company that specializes in developing innovative tools and technologies for genomic analysis. The company operates primarily in the life sciences sector, providing products and services designed for researchers in genomics, proteomics, and cellular analysis. Standard BioTools' core offerings include advanced sequencing technologies, microfluidic devices, and software solutions that facilitate high-throughput data generation and analysis, empowering scientists to make breakthroughs in personalized medicine and biological research.
LAB Company Deck
LAB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a well-managed quarter with robust strategic initiatives and strong cost management, despite facing significant revenue declines and challenges in the U.S. academic market. The company's strong cash position and strategic product expansions provide a positive outlook, though the impact of tariffs and revenue declines remain concerns.View all LAB earnings summariesLAB Stock 12 Month Forecast
Average Price Target
$1.55
▲(19.23% Upside)
Technical Analysis
Ownership Overview
27.49% Insiders
8.09% Mutual Funds
0.51% Other Institutional Investors
54.21% Public Companies and
Individual Investors